Neuroimaging in Parkinson disease: from research setting to clinical practice
暂无分享,去创建一个
[1] E. Bézard,et al. Alterations of striatal NMDA receptor subunits associated with the development of dyskinesia in the MPTP-lesioned primate model of Parkinson's disease , 2005, Neuropharmacology.
[2] M Schulzer,et al. Biochemical variations in the synaptic level of dopamine precede motor fluctuations in Parkinson's disease: PET evidence of increased dopamine turnover. , 2001, Annals of neurology.
[3] Keith A. Johnson,et al. Amyloid is linked to cognitive decline in patients with Parkinson disease without dementia , 2013, Neurology.
[4] Chris C. Tang,et al. Abnormalities in Metabolic Network Activity Precede the Onset of Motor Symptoms in Parkinson's Disease , 2010, The Journal of Neuroscience.
[5] Marios Politis,et al. Serotonergic Neurons Mediate Dyskinesia Side Effects in Parkinson’s Patients with Neural Transplants , 2010, Science Translational Medicine.
[6] S. Studenski,et al. History of falls in Parkinson disease is associated with reduced cholinergic activity , 2009, Neurology.
[7] Klaus P. Ebmeier,et al. Diffusion tensor imaging in parkinsonian syndromes , 2013, Neurology.
[8] K. Chaudhuri,et al. Non-motor symptoms of Parkinson's disease: diagnosis and management , 2006, The Lancet Neurology.
[9] D. Aarsland,et al. A systematic review of prevalence studies of dementia in Parkinson's disease , 2005, Movement disorders : official journal of the Movement Disorder Society.
[10] R. Albin,et al. Aβ-amyloid deposition in patients with Parkinson disease at risk for development of dementia , 2012, Neurology.
[11] R. Felix,et al. Combined 123I-FP-CIT and 123I-IBZM SPECT for the diagnosis of parkinsonian syndromes: study on 72 patients , 2005, Journal of Neural Transmission.
[12] T. Yen,et al. Correlation of Parkinson disease severity and 18F-DTBZ positron emission tomography. , 2014, JAMA neurology.
[13] M. Politis. C O M M E N T a R Y Open Access , 2022 .
[14] A. Björklund,et al. Dyskinesias following neural transplantation in Parkinson's disease , 2002, Nature Neuroscience.
[15] R. Buchert,et al. [18F]FDG-PET is superior to [123I]IBZM-SPECT for the differential diagnosis of parkinsonism , 2012, Neurology.
[16] P. Piccini,et al. Functional Neural Transplantation III , 2012 .
[17] F. Turkheimer,et al. Serotonergic mechanisms responsible for levodopa-induced dyskinesias in Parkinson's disease patients. , 2014, The Journal of clinical investigation.
[18] P. Piccini,et al. Parkinson disease and impulse control disorders: a review of clinical features, pathophysiology and management , 2009, Postgraduate Medical Journal.
[19] B. Winblad,et al. An Estimate of the Worldwide Prevalence and Direct Costs of Dementia in 2003 , 2006, Dementia and Geriatric Cognitive Disorders.
[20] G. Duncan. The aging brain and neurodegenerative diseases. , 2011, Clinics in geriatric medicine.
[21] B U Meyer,et al. Brain parenchyma sonography discriminates Parkinson’s disease and atypical parkinsonian syndromes , 2002, Neurology.
[22] T. Vogt,et al. The dopamine D2 receptor ligand 18F-desmethoxyfallypride: an appropriate fluorinated PET tracer for the differential diagnosis of parkinsonism , 2004, European Journal of Nuclear Medicine and Molecular Imaging.
[23] F. Niccolini,et al. Serotonin in Parkinson's disease , 2015, Behavioural Brain Research.
[24] Marios Politis,et al. Neural response to visual sexual cues in dopamine treatment-linked hypersexuality in Parkinson's disease. , 2013, Brain : a journal of neurology.
[25] V. Sossi,et al. Longitudinal progression of sporadic Parkinson's disease: a multi-tracer positron emission tomography study. , 2009, Brain : a journal of neurology.
[26] Transcranial sonography and [18F]fluorodeoxyglucose positron emission tomography for the differential diagnosis of parkinsonism: a head‐to‐head comparison , 2014, European journal of neurology.
[27] V. Sossi,et al. In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson's disease , 2000, Annals of neurology.
[28] A. M. Ortiz,et al. Clinical features and 123I-FP-CIT SPECT imaging in vascular parkinsonism and Parkinson's disease , 2012, Journal of Neurology, Neurosurgery & Psychiatry.
[29] P. David Mozley,et al. Logistic discriminant parametric mapping: a novel method for the pixel-based differential diagnosis of Parkinson’s disease , 1999, European Journal of Nuclear Medicine.
[30] S. Houle,et al. Increased striatal dopamine release in Parkinsonian patients with pathological gambling: a [11C] raclopride PET study. , 2009, Brain : a journal of neurology.
[31] N. Kumar,et al. The Sydney Multicenter Study of Parkinson's Disease: The Inevitability of Dementia at 20 years , 2009 .
[32] D. Michalek,et al. Weight change and body composition in patients with Parkinson's disease. , 1995, Journal of the American Dietetic Association.
[33] P. Piccini,et al. In vivo imaging of the integration and function of nigral grafts in clinical trials. , 2012, Progress in brain research.
[34] C. Tanner,et al. Levodopa and the progression of Parkinson's disease. , 2004, The New England journal of medicine.
[35] S. Asenbaum,et al. [123I]β-CIT and SPECT in essential tremor and Parkinson's disease , 1998, Journal of Neural Transmission.
[36] M. Politis. Optimizing functional imaging protocols for assessing the outcome of fetal cell transplantation in Parkinson's disease , 2011, BMC medicine.
[37] B. Schölkopf,et al. MR-Based PET attenuation correction for PET/MR imaging. , 2013, Seminars in nuclear medicine.
[38] Matthias Reimold,et al. The specificity and sensitivity of transcranial ultrasound in the differential diagnosis of Parkinson's disease: a prospective blinded study , 2008, The Lancet Neurology.
[39] R. Chervin,et al. Symptoms of rapid eye movement sleep behavior disorder are associated with cholinergic denervation in Parkinson disease , 2012, Annals of neurology.
[40] Joachim Hornegger,et al. Self-gated Radial MRI for Respiratory Motion Compensation on Hybrid PET/MR Systems , 2013, MICCAI.
[41] Akinori Nakamura,et al. Visual hallucination in Parkinson's disease with FDG PET , 2004, Movement disorders : official journal of the Movement Disorder Society.
[42] Robert B. Innis,et al. [123I]β‐CIT SPECT imaging demonstrates reduced density of striatal dopamine transporters in Parkinson's disease and multiple system atrophy , 2001 .
[43] C. Freed,et al. Transplantation of fetal mesencephalic tissue in Parkinson's disease. , 1995, The New England journal of medicine.
[44] J R Moeller,et al. Early differential diagnosis of Parkinson's disease with 18F‐fluorodeoxyglucose and positron emission tomography , 1995, Neurology.
[45] Vesna Sossi,et al. Biochemical variations in the synaptic level of dopamine precede motor fluctuations in Parkinson's disease: PET evidence of increased dopamine turnover , 2001 .
[46] John Seibyl,et al. Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. Parkinson Study Group. , 2000, JAMA.
[47] J. Nutt,et al. Parkinson's disease , 2004, The Lancet.
[48] D. Brooks,et al. Tremor in Parkinson’s disease and serotonergic dysfunction , 2003, Neurology.
[49] G Tedeschi,et al. Regional Gray Matter Atrophy in Patients with Parkinson Disease and Freezing of Gait , 2012, American Journal of Neuroradiology.
[50] T. Ishikawa,et al. Comparative nigrostriatal dopaminergic imaging with iodine-123-beta CIT-FP/SPECT and fluorine-18-FDOPA/PET. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[51] M. Emre. Dementia associated with Parkinson's disease , 2003, The Lancet Neurology.
[52] B. Giraudeau,et al. Quantitative analysis of striatal dopamine D2 receptors with 123I-iodolisuride SPECT in degenerative extrapyramidal diseases , 2001, Nuclear medicine communications.
[53] Satoshi Minoshima,et al. Alzheimer's disease versus dementia with Lewy bodies: Cerebral metabolic distinction with autopsy confirmation , 2001, Annals of neurology.
[54] D. Brooks,et al. Direct brain infusion of glial cell line–derived neurotrophic factor in Parkinson disease , 2003, Nature Medicine.
[55] Claude Nahmias,et al. Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL‐PET study , 2003, Annals of neurology.
[56] J. Shine,et al. Exploring the cortical and subcortical functional magnetic resonance imaging changes associated with freezing in Parkinson's disease. , 2013, Brain : a journal of neurology.
[57] Alan A. Wilson,et al. Elevated serotonin transporter binding in depressed patients with Parkinson's disease: A preliminary PET study with [11C]DASB , 2008, Movement disorders : official journal of the Movement Disorder Society.
[58] R. Hilker,et al. Dementia in Parkinson disease , 2005, Neurology.
[59] G. Sawle,et al. Separating Parkinson's disease from normality. Discriminant function analysis of fluorodopa F 18 positron emission tomography data. , 1994, Archives of neurology.
[60] Keith A. Johnson,et al. Imaging amyloid deposition in Lewy body diseases , 2008, Neurology.
[61] G. Bernardi,et al. High endogenous cannabinoid levels in the cerebrospinal fluid of untreated Parkinson's disease patients , 2005, Annals of neurology.
[62] Ian Law,et al. Combined PET/MR imaging in neurology: MR-based attenuation correction implies a strong spatial bias when ignoring bone , 2014, NeuroImage.
[63] C D Marsden,et al. Differing patterns of striatal 18F‐dopa uptake in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy , 1990, Annals of neurology.
[64] J D Speelman,et al. [123I]FP-CIT SPECT shows a pronounced decline of striatal dopamine transporter labelling in early and advanced Parkinson's disease. , 1997, Journal of neurology, neurosurgery, and psychiatry.
[65] Stanley Fahn,et al. Dyskinesia after fetal cell transplantation for parkinsonism: A PET study , 2002, Annals of neurology.
[66] D. Dickson,et al. Sensitivity and specificity of three clinical criteria for dementia with Lewy bodies in an autopsy‐verified sample , 1999, International journal of geriatric psychiatry.
[67] P. Thompson,et al. Isolated tremor and disruption of the nigrostriatal dopaminergic system , 1992, Neurology.
[68] Vesna Sossi,et al. A double‐blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease , 2003, Annals of neurology.
[69] A. Kessels,et al. Meta-analysis of the literature on diagnostic accuracy of SPECT in parkinsonian syndromes , 2007, BMC neurology.
[70] Anna Barnes,et al. FDG PET in the differential diagnosis of parkinsonian disorders , 2005, NeuroImage.
[71] Joon-Kee Yoon,et al. A comparison of cerebral glucose metabolism in Parkinson's disease, Parkinson's disease dementia and dementia with Lewy bodies , 2007, European journal of neurology.
[72] B. Bloem,et al. [123I]β‐CIT SPECT distinguishes vascular parkinsonism from Parkinson's disease , 2002, Movement disorders : official journal of the Movement Disorder Society.
[73] K. Riklund,et al. Degenerative changes were common in brain magnetic resonance imaging in patients with newly diagnosed Parkinson’s disease in a population-based cohort , 2009, Journal of Neurology.
[74] M. Girolami,et al. Automated, High Accuracy Classification of Parkinsonian Disorders: A Pattern Recognition Approach , 2013, PloS one.
[75] Angelo Antonini,et al. Cost‐effectiveness of 123I‐FP‐CIT SPECT in the differential diagnosis of essential tremor and Parkinson's disease in Italy , 2008, Movement disorders : official journal of the Movement Disorder Society.
[76] Daniela Berg,et al. Echogenicity of the substantia nigra in Parkinson's disease and its relation to clinical findings , 2001, Journal of Neurology.
[77] C. Kirsch,et al. SPECT imaging of dopamine D2 receptors with 123I‐IBZM: initial experience in controls and patients with Parkinson's syndrome and Wilson's disease , 1991, Nuclear medicine communications.
[78] D. Brooks,et al. Fatigue in Parkinson's disease is linked to striatal and limbic serotonergic dysfunction. , 2010, Brain : a journal of neurology.
[79] A. J. Stoessl,et al. Evidence for impaired presynaptic dopamine function in parkinsonian patients with motor fluctuations , 2000, Journal of Neural Transmission.
[80] A. Righini,et al. Thin Section MR Study of the Basal Ganglia in the Differential Diagnosis Between Striatonigral Degeneration and Parkinson Disease , 2002, Journal of computer assisted tomography.
[81] C Kremser,et al. Diffusion-weighted MRI differentiates the Parkinson variant of multiple system atrophy from PD , 2002, Neurology.
[82] S. Aalto,et al. A follow‐up study on 6‐[18F]fluoro‐L‐dopa uptake in early Parkinson's disease shows nonlinear progression in the putamen , 2009, Movement disorders : official journal of the Movement Disorder Society.
[83] L. Friberg,et al. Clinical impact of diagnostic SPET investigations with a dopamine re-uptake ligand , 2002, European Journal of Nuclear Medicine and Molecular Imaging.
[84] Alexander Hammers,et al. Glutamate NMDA receptor dysregulation in Parkinson's disease with dyskinesias. , 2011, Brain : a journal of neurology.
[85] J. Olin,et al. A responder analysis of memantine treatment in patients with Alzheimer disease maintained on donepezil. , 2006, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.
[86] D. Brooks,et al. Serotonergic loss in motor circuitries correlates with severity of action-postural tremor in PD , 2013, Neurology.
[87] C. Rowe,et al. In vivo assessment of vesicular monoamine transporter type 2 in dementia with lewy bodies and Alzheimer disease. , 2011, Archives of neurology.
[88] W. Oertel,et al. 123I‐IBZM binding compared with long‐term clinical follow up in patients with de novo parkinsonism , 1998, Movement disorders : official journal of the Movement Disorder Society.
[89] M. S. Lee,et al. The pedunculopontine nucleus: its role in the genesis of movement disorders. , 2000, Yonsei medical journal.
[90] V. Dhawan,et al. Changes in network activity with the progression of Parkinson's disease. , 2007, Brain : a journal of neurology.
[91] E. Tolosa,et al. Progression of cortical thinning in early Parkinson's disease , 2012, Movement disorders : official journal of the Movement Disorder Society.
[92] Johannes C. Klein,et al. Neurotransmitter changes in dementia with Lewy bodies and Parkinson disease dementia in vivo , 2010, Neurology.
[93] Wim E J Weber,et al. Specificity and sensitivity of transcranial sonography of the substantia nigra in the diagnosis of Parkinson's disease: prospective cohort study in 196 patients , 2013, BMJ Open.
[94] Matthias Reimold,et al. [11C]PIB binding in Parkinson's disease dementia , 2008, NeuroImage.
[95] S. Houle,et al. Serotonin 2A receptors and visual hallucinations in Parkinson disease. , 2010, Archives of neurology.
[96] F. Niccolini,et al. Dyskinesias in Parkinson's disease: views from positron emission tomography studies , 2014, European Journal of Neurology.
[97] Marios Politis,et al. Clinical application of stem cell therapy in Parkinson's disease , 2012, BMC Medicine.
[98] Yen F. Tai,et al. Compulsive drug use linked to sensitized ventral striatal dopamine transmission , 2006, Annals of neurology.
[99] T. Robbins,et al. The catechol-O-methyltransferase Val(158)Met polymorphism modulates fronto-cortical dopamine turnover in early Parkinson's disease: a PET study. , 2012, Brain : a journal of neurology.
[100] S. Houle,et al. Drug-induced deactivation of inhibitory networks predicts pathological gambling in PD , 2010, Neurology.
[101] Yasuhiro Nakata,et al. Differential Diagnosis Tool for Parkinsonian Syndrome Using Multiple Structural Brain Measures , 2013, Comput. Math. Methods Medicine.
[102] R. Albin,et al. Cerebral metabolic differences in Parkinson's and Alzheimer's diseases matched for dementia severity. , 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[103] S Tanada,et al. Positron emission tomographic measurement of acetylcholinesterase activity reveals differential loss of ascending cholinergic systems in Parkinson's disease and progressive supranuclear palsy , 1999, Annals of neurology.
[104] Nick C. Fox,et al. Voxel-based morphometry detects patterns of atrophy that help differentiate progressive supranuclear palsy and Parkinson's disease , 2004, NeuroImage.
[105] S Minoshima,et al. Diagnosis and management of dementia with Lewy bodies , 2005, Neurology.
[106] D. Brooks,et al. Serotonergic mediated body mass index changes in Parkinson's disease , 2011, Neurobiology of Disease.
[107] Constantinos Kallis,et al. Lewy- and Alzheimer-type pathologies in Parkinson's disease dementia: which is more important? , 2011, Brain : a journal of neurology.
[108] Perry E. Radau,et al. Does combined imaging of the pre- and postsynaptic dopaminergic system increase the diagnostic accuracy in the differential diagnosis of parkinsonism? , 2007, European Journal of Nuclear Medicine and Molecular Imaging.
[109] A. Maes,et al. Cost‐effectiveness of 18F‐fluorodeoxyglucose positron emission tomography in the assessment of early dementia from a Belgian and European perspective , 2005, European journal of neurology.
[110] Jungsu S. Oh,et al. Differential Diagnosis of Parkinsonism Using Dual-Phase F-18 FP-CIT PET Imaging , 2013, Nuclear Medicine and Molecular Imaging.
[111] T. Suhara,et al. Mapping of brain acetylcholinesterase alterations in Lewy body disease by PET , 2009, Neuroscience Research.
[112] F. Niccolini,et al. Dopamine receptor mapping with PET imaging in Parkinson’s disease , 2014, Journal of Neurology.
[113] M. Filippi,et al. Pattern of brain tissue loss associated with freezing of gait in Parkinson disease , 2012, Neurology.
[114] C. Claussen,et al. Simultaneous Mr/pet Imaging of the Human Brain: Feasibility Study 1 , 2022 .
[115] D. Brooks,et al. Depressive symptoms in PD correlate with higher 5-HTT binding in raphe and limbic structures , 2010, Neurology.
[116] Nick C Fox,et al. Quantitative MRI measurement of superior cerebellar peduncle in progressive supranuclear palsy , 2005, Neurology.
[117] I. McKeith,et al. Striatal dopamine transporter in dementia with Lewy bodies and Parkinson disease , 2004, Neurology.
[118] G. Linazasoro,et al. IMAGING β-AMYLOID BURDEN IN AGING AND DEMENTIA , 2008, Neurology.
[119] D J Brooks,et al. Alterations in opioid receptor binding in Parkinson's disease patients with levodopa‐induced dyskinesias , 1997, Annals of neurology.
[120] William M. Wells,et al. Medical Image Computing and Computer-Assisted Intervention — MICCAI’98 , 1998, Lecture Notes in Computer Science.
[121] Yen F. Tai,et al. Clinical correlates of levodopa-induced dopamine release in Parkinson disease , 2006, Neurology.
[122] M Schulzer,et al. PET demonstrates reduced dopamine transporter expression in PD with dyskinesias , 2009, Neurology.
[123] V. Sossi,et al. Age‐specific progression of nigrostriatal dysfunction in Parkinson's disease , 2011, Annals of neurology.
[124] Yasuo Terayama,et al. Changes in substantia nigra and locus coeruleus in patients with early-stage Parkinson's disease using neuromelanin-sensitive MR imaging , 2013, Neuroscience Letters.
[125] A. Lees,et al. Ageing and Parkinson's disease: substantia nigra regional selectivity. , 1991, Brain : a journal of neurology.
[126] Tarek A. Yousry,et al. Neurology: A Queen Square Textbook , 2009 .
[127] J. Olesen,et al. The economic cost of brain disorders in Europe , 2012, European journal of neurology.
[128] J. Larsen,et al. Measuring fatigue in patients with Parkinson's disease – the Fatigue Severity Scale , 2002, European journal of neurology.
[129] N. Bohnen,et al. Cortical cholinergic function is more severely affected in parkinsonian dementia than in Alzheimer disease: an in vivo positron emission tomographic study. , 2003, Archives of neurology.
[130] Björn Gustavii,et al. Short‐ and long‐term survival and function of unilateral intrastriatal dopaminergic grafts in Parkinson's disease , 1997, Annals of neurology.
[131] R. P. Maguire,et al. Striatal dopa and glucose metabolism in PD patients with freezing of gait , 2006, Movement disorders : official journal of the Movement Disorder Society.
[132] Ciprian Catana,et al. PET/MRI for Neurologic Applications , 2012, The Journal of Nuclear Medicine.
[133] J. Roerdink,et al. Validation of parkinsonian disease‐related metabolic brain patterns , 2013, Movement disorders : official journal of the Movement Disorder Society.
[134] C. Rowe,et al. Amyloid load in Parkinson’s disease dementia and Lewy body dementia measured with [11C]PIB positron emission tomography , 2008, Journal of Neurology, Neurosurgery, and Psychiatry.
[135] S. Kitamura,et al. Adenosine A2A Receptors Measured with [11C]TMSX PET in the Striata of Parkinson's Disease Patients , 2011, PloS one.
[136] A. Stefani,et al. The relationship between cerebral vascular disease and parkinsonism: The VADO study. , 2012, Parkinsonism & related disorders.
[137] L. Reneman,et al. Effect of age and gender on dopamine transporter imaging with [123I]FP-CIT SPET in healthy volunteers , 2000, European Journal of Nuclear Medicine.
[138] Thomas Behr,et al. Dopamine transporter imaging and SPECT in diagnostic work‐up of Parkinson's disease: A decision‐analytic approach , 2003, Movement disorders : official journal of the Movement Disorder Society.
[139] Claire Henchcliffe,et al. Usefulness of Proton and Phosphorus MR Spectroscopic Imaging for Early Diagnosis of Parkinson's Disease , 2015, Journal of neuroimaging : official journal of the American Society of Neuroimaging.
[140] J. Seibyl,et al. [123I]β-CIT SPECT imaging assessment of the rate of Parkinson’s disease progression , 2001, Neurology.
[141] C Kremser,et al. Diffusion-weighted imaging discriminates progressive supranuclear palsy from PD, but not from the parkinson variant of multiple system atrophy , 2003, Neurology.
[142] Karl Herholz,et al. Nonlinear progression of Parkinson disease as determined by serial positron emission tomographic imaging of striatal fluorodopa F 18 activity. , 2005, Archives of neurology.
[143] A. Lees,et al. [123I] FP‐CIT spect study in vascular parkinsonism and Parkinson's disease , 2007, Movement disorders : official journal of the Movement Disorder Society.
[144] Gudrun Wagenknecht,et al. MRI for attenuation correction in PET: methods and challenges , 2012, Magnetic Resonance Materials in Physics, Biology and Medicine.
[145] A. Björklund,et al. Serotonin Neuron Loss and Nonmotor Symptoms Continue in Parkinson’s Patients Treated with Dopamine Grafts , 2012, Science Translational Medicine.
[146] D. Dressler,et al. Sonographic discrimination of corticobasal degeneration vs progressive supranuclear palsy , 2004, Neurology.
[147] H. Groenewegen,et al. [Impulse control disorders in Parkinson's disease]. , 2011, Tijdschrift voor psychiatrie.
[148] M. Sasaki,et al. Differences in the reduced 18F-Dopa uptakes of the caudate and the putamen in Parkinson's disease: correlations with the three main symptoms , 1996, Journal of the Neurological Sciences.
[149] Vesna Sossi,et al. Levodopa-induced changes in synaptic dopamine levels increase with progression of Parkinson's disease: implications for dyskinesias. , 2004, Brain : a journal of neurology.
[150] S. Leurgans,et al. Hallucinations and sleep disorders in PD , 2005, Neurology.
[151] Francis R. Loayza,et al. Cortical hypoperfusion in Parkinson's disease assessed using arterial spin labeled perfusion MRI , 2012, NeuroImage.
[152] Mrc Psych,et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): Report of the consortium on DLB international workshop , 1996 .
[153] R. Chervin,et al. The Role of Serotonin in Sleep Disordered Breathing Associated with Parkinson Disease: A Correlative [11C]DASB PET Imaging Study , 2012, PloS one.
[154] W. Heiss,et al. [18F]fluorodopa uptake in the upper brainstem measured with positron emission tomography correlates with decreased REM sleep duration in early Parkinson's disease , 2003, Clinical Neurology and Neurosurgery.
[155] Nora Turjanski,et al. Depression in Parkinson's disease: loss of dopamine and noradrenaline innervation in the limbic system. , 2005, Brain : a journal of neurology.
[156] K. L. Leenders,et al. Comparison of FP-CIT SPECT with F-DOPA PET in patients with de novo and advanced Parkinson’s disease , 2006, European Journal of Nuclear Medicine and Molecular Imaging.
[157] D J Brooks,et al. Differential diagnosis of Parkinson's disease, multiple system atrophy, and Steele-Richardson-Olszewski syndrome: discriminant analysis of striatal 18F-dopa PET data. , 1994, Journal of neurology, neurosurgery, and psychiatry.
[158] F. Vingerhoets,et al. Which clinical sign of Parkinson's disease best reflects the nigrostriatal lesion? , 1997, Annals of neurology.
[159] L. Wojtecki,et al. Diagnostic Accuracy of Combined FP-CIT, IBZM, and MIBG Scintigraphy in the Differential Diagnosis of Degenerative Parkinsonism: A Multidimensional Statistical Approach , 2011, The Journal of Nuclear Medicine.
[160] F. Turkheimer,et al. Adenosine 2A receptor availability in dyskinetic and nondyskinetic patients with Parkinson disease , 2011, Neurology.
[161] J. Trojanowski,et al. Imaging of Tau Pathology in a Tauopathy Mouse Model and in Alzheimer Patients Compared to Normal Controls , 2013, Neuron.
[162] Ajay S. Kurani,et al. Differences in brain activation between tremor- and nontremor-dominant Parkinson disease. , 2012, JAMA neurology.
[163] 이필휴. A comparison of cerebral glucose metabolism in Parkinson's disease, Parkinson's disease dementia and dementia with Lewy bodies , 2007 .
[164] L. Tremblay,et al. Role of serotonergic 1A receptor dysfunction in depression associated with Parkinson's disease , 2012, Movement disorders : official journal of the Movement Disorder Society.
[165] Jian Wang,et al. Characterizing iron deposition in Parkinson's disease using susceptibility-weighted imaging: An in vivo MR study , 2010, Brain Research.
[166] D. Brooks,et al. Staging of serotonergic dysfunction in Parkinson's Disease: An in vivo 11C-DASB PET study , 2010, Neurobiology of Disease.
[167] Chris C. Tang,et al. Differential diagnosis of parkinsonism: a metabolic imaging study using pattern analysis , 2010, The Lancet Neurology.
[168] B. Choe,et al. Different metabolic patterns analysis of Parkinsonism on the 18F-FDG PET. , 2004, European journal of radiology.
[169] O. Lindvall,et al. Graft‐induced dyskinesias in Parkinson's disease: High striatal serotonin/dopamine transporter ratio , 2011, Movement disorders : official journal of the Movement Disorder Society.
[170] A. Snyder,et al. Resting state functional connectivity of the striatum in Parkinson's disease. , 2012, Brain : a journal of neurology.
[171] A. Björklund,et al. Long-term clinical outcome of fetal cell transplantation for Parkinson disease: two case reports. , 2014, JAMA neurology.
[172] C. Marsden,et al. Bilateral caudate and putamen grafts of embryonic mesencephalic tissue treated with lazaroids in Parkinson's disease. , 2000, Brain : a journal of neurology.
[173] Oliver Pogarell,et al. Prospective study of presynaptic dopaminergic imaging in patients with mild parkinsonism and tremor disorders: Part 1. Baseline and 3‐month observations , 2003, Movement disorders : official journal of the Movement Disorder Society.
[174] Marios Politis,et al. Parkinson's disease symptoms: The patient's perspective , 2010, Movement disorders : official journal of the Movement Disorder Society.
[175] Akinori Nakamura,et al. Cognitive- and motor-related regions in Parkinson's disease: FDOPA and FDG PET studies , 2004, NeuroImage.
[176] Marios Politis,et al. Cue-induced striatal dopamine release in Parkinson's disease-associated impulsive-compulsive behaviours. , 2011, Brain : a journal of neurology.
[177] Akinori Nakamura,et al. Striatal and extrastriatal dysfunction in Parkinson's disease with dementia: a 6-[18F]fluoro-L-dopa PET study. , 2002, Brain : a journal of neurology.
[178] David J. Brooks,et al. Evidence of dopamine dysfunction in the hypothalamus of patients with Parkinson's disease: An in vivo 11C-raclopride PET study , 2008, Experimental Neurology.
[179] P. Pollak,et al. The relation of putamen and caudate nucleus 18F-Dopa uptake to motor and cognitive performances in Parkinson’s disease , 1999, Journal of the Neurological Sciences.
[180] David J. Brooks,et al. Progression of monoaminergic dysfunction in Parkinson's disease: A longitudinal 18F-dopa PET study , 2011, NeuroImage.
[181] Merja Haaparanta,et al. Rate of progression in Parkinson's disease: A 6‐[18F]fluoro‐L‐dopa PET study , 2001, Movement disorders : official journal of the Movement Disorder Society.